Senestech Inc SEC Filings

SenesTech, Inc. (SNES)1 share of common stock on 11/14/2025 at a price of $2.75 per share. Following this transaction, the reporting person held 0 shares of SenesTech common stock in direct ownership. The filing is signed by /s/ Thomas C. Chesterman, Attorney-in-Fact on 11/17/2025.

SenesTech (SNES) appointed Michael Edell as Interim Chief Operating Officer and outlined his compensation terms. The role is effective November 3, 2025, with an employment offer letter executed on November 7, 2025.

Edell will receive $30,000 per month and may earn bonuses of up to $25,000 for Q4 2025 and up to $30,000 for Q1 2026, subject to Board discretion. The agreement runs for six months on an at‑will basis. Either party may terminate with 60 days’ notice; the company can immediately relieve duties while continuing salary during the notice period. No additional compensation or benefits are provided unless authorized in writing, apart from requirements under California law, and Edell is restricted from competing during employment.

SenesTech (SNES) filed its Q3 2025 report, highlighting improved growth and liquidity. Revenue reached $690,000, up 43% year over year, driven largely by the Evolve product line, while ContraPest declined. Gross profit was $433,000 with a 62.8% margin in the quarter; for the first nine months, revenue was $1.8 million with a 64.2% gross margin. Net loss narrowed to $1.3 million for the quarter.

Management reports that prior substantial doubt about continuing as a going concern has been alleviated. During 2025, financing transactions generated $13.2 million in net proceeds, and cash, cash equivalents and short‑term investments totaled $10.2 million as of September 30, 2025, supporting at least the next 12 months. The company ended the period with 5,223,015 shares outstanding as of November 7, 2025. Operating cash use improved versus last year, and higher interest income reflected larger average balances.

Evolve Rat and Evolve Mouse now comprise the majority of sales across e‑commerce, professional, and retail channels. Operating expenses were stable year over year as cost containment offset higher legal and franchise fees. An at‑the‑market program added $2.7 million year to date, and warrant exercises added $10.5 million, bolstering liquidity while the company works toward higher‑margin growth.

SenesTech (SNES) announced its third‑quarter results for the period ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1 to a Form 8‑K under Item 2.02.

The disclosure is presented as furnished, not filed, under the Exchange Act. The company also stated it has no obligation to publicly update forward‑looking statements. The text referenced in the report may be available on www.senestech.com.

SenesTech (SNES) reported an insider ownership update via Form 3 for an officer serving as Interim Chief Operating Officer. The filing indicates no securities are beneficially owned (0) by the reporting person. The event date was 10/15/2025, and the form was filed by one reporting person.

The document was executed by Thomas C. Chesterman as attorney-in-fact.

SenesTech, Inc. (SNES) appointed Michael Edell as Interim Chief Operating Officer effective October 15, 2025. The company states there are no family relationships and no arrangements or understandings related to his election.

Edell will receive $30,000 per month and is eligible for a bonus at the Board’s discretion. Given the interim status, he will not receive standard benefits such as health insurance, retirement plans, paid time off, or other fringe benefits, and he will not be entitled to severance or other post‑termination compensation. He will be reimbursed for reasonable business expenses and will enter into the company’s standard indemnification agreement for officers.

SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.

The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.